Study guide

9.3 Agent Classes & Organ-System Toxic Responses

DABT: Diplomate of the American Board of Toxicology Exam

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Study Design Fundamentals

1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration

2 Dose Selection, Controls & Biostatistics in Toxicology

2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

3 Study Execution, GLP Compliance & Quality Assurance

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections

4 Executing In Vivo, In Vitro, In Silico & Field Studies

4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization

5 Clinical Pathology & Toxicologic Pathology

5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

6 Specialized Toxicological Study Endpoints

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology

7 Toxicokinetics & Biotransformation

7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification

8 Cellular Mechanisms of Toxicity & Organ Pathogenesis

8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

9 Hazard Identification & Evidence Integration

9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses

10 Mode of Action, AOPs & Non-Cancer Endpoints

10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects

11 Exposure Assessment Methodologies & Quantification

11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

12 Quantitative Dose-Response Principles & Point of Departure Derivation

12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose

13 Health-Based Guidance Value Derivation & Uncertainty Factors

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)

14 Risk Characterization for Non-Cancer & Cancer Health Effects

14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization

15 Risk Management, Occupational Exposure Limits & Environmental Standards

15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations

16 Regulatory Frameworks & Product Stewardship

16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH

17 Clinical Toxicology & Medical Management of Poisoning

17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies

18 Environmental, Ecological & Public Health Toxicology

18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation

9.3 Agent Classes & Organ-System Toxic Responses

Key Takeaways Explain This Topic AI

Organophosphate and carbamate insecticides inhibit acetylcholinesterase; pyrethroids act on voltage-gated sodium channels; paraquat redox-cycles in alveolar pneumocytes and causes delayed pulmonary fibrosis—not an AChE toxidrome.

Lead injures heme synthesis and the developing brain; methylmercury targets CNS; inorganic mercury and cadmium target kidney; arsenic injures skin and is a human cancer hazard; chromium(VI) inhalation targets lung and nasal mucosa.

Benzene injures marrow; carbon tetrachloride injures centrilobular liver; n-hexane causes giant axonal neuropathy via 2,5-hexanedione; methanol’s formate metabolite injures the optic nerve.

A whole-body X-ray absorbed dose of about 0.1 Gy typically produces no acute clinical radiation syndrome; stochastic cancer hazard remains a protection concern, while frank hematopoietic syndrome appears near 1 Gy and above.

Ethanol (fetal alcohol spectrum), therapeutic retinoids (neural-crest/craniofacial), valproate (neural-tube defects), and ACE inhibitors (late-pregnancy renal/oligohydramnios sequence) are high-yield developmental toxicant patterns.

Last updated: September 2026

A teaching survey, not a catalogue

Handbook III.A.1 D–E asks you to recognize classes of agents and the organ systems they typically injure so that hazard identification has somewhere to look. Independent ExamFinch coverage here is a survey : enough mechanism and target-organ logic to interpret a novel stem. It is not a complete toxicant encyclopedia and not an ABT sample-item bank. ExamFinch does not claim official approval, review, or partnership with ABT.

When several organs could be named, ask portal of entry , bioactivation site , transporter , and repair reserve . Those four questions explain why inhaled chromium(VI) is a lung-cancer story, why carbon tetrachloride is a centrilobular-liver story, and why methanol is an optic-nerve story.

Pesticides

Organophosphate (OP) insecticides phosphorylate acetylcholinesterase (AChE) . Acetylcholine accumulates at muscarinic and nicotinic synapses and in the CNS: DUMBBELS-type muscarinic signs, fasciculations and weakness, and seizures in severe cases. Some OPs age on the enzyme, so reactivation with oximes is time-limited. A subset (historical tri-ortho-cresyl phosphate teaching) also inhibits neuropathy target esterase (NTE) and produces organophosphate-induced delayed neuropathy —a dying-back axonopathy days to weeks later, not the acute cholinergic crisis.

Carbamates carbamylate AChE. The bond is reversible and does not age in the OP sense, so the toxidrome is usually shorter, and oxime use is not the same decision as for a dialkyl OP. Red-cell AChE (and sometimes plasma butyrylcholinesterase) is the chemical-specific biomarker of effect from section 5.3’s toolkit, not a liver enzyme.

Pyrethroids do not inhibit AChE. They prolong voltage-gated sodium channel opening. Type I (non-cyano) compounds produce a tremor syndrome; Type II (α-cyano) compounds produce choreoathetosis and salivation. Treating every “insecticide” as an OP is the class error this paragraph exists to prevent.

Paraquat , a bipyridyl herbicide , is a different organ story. It undergoes redox cycling , is taken up by the polyamine transporter into type I and type II alveolar pneumocytes , and produces delayed pulmonary fibrosis after a stormy, often lethal oral exposure. Gastrointestinal absorption is incomplete, but the lung still sees enough. Paraquat is not an AChE inhibitor and not a pyrethroid sodium-channel story.

Metals

Lead inhibits δ-aminolevulinic acid dehydratase (ALAD) and ferrochelatase, producing anemia and elevated zinc protoporphyrin; basophilic stippling is a teaching smear finding. The developing brain is the critical-effect organ for public-health hazard identification: IQ loss at blood-lead levels far below those that produce abdominal colic or wrist drop in adults. Kidney (intranuclear inclusions historically) and hypertension are additional targets.

Mercury must be split by species. Elemental mercury vapor targets lung (chemical pneumonitis at high concentration) and CNS (tremor, erethism). Inorganic mercuric salts target the proximal tubule . Methylmercury targets CNS , especially the developing brain (Minamata-type teaching): neurons more than kidney. A stem that says only “mercury” without the species is incomplete.

Inorganic arsenic (arsenite more than arsenate in many toxicodynamic discussions) produces skin pigmentation and keratosis, peripheral neuropathy, cardiovascular disease, and human cancers of skin, lung, and urinary bladder —a durable epidemiologic hazard identification. Cadmium binds metallothionein , injures the proximal tubule (low-molecular-weight proteinuria), contributes to bone disease in the historical Itai-itai outbreak, and is a lung-cancer hazard by inhalation. Chromium(VI) (chromate) is a lung and nasal inhalation-cancer and irritation hazard; reduction to Cr(III) limits bioavailability, which is why the oxidation state belongs in the hazard statement.

Solvents and vapors

Benzene is a bone-marrow toxicant: aplastic anemia, myelodysplasia, and acute myeloid leukemia . Other alkylbenzenes (toluene, xylene) are not interchangeable marrow carcinogens; do not promote every “aromatic solvent” to benzene’s hazard.

Carbon tetrachloride is bioactivated by CYP2E1 (and related isoforms) to the trichloromethyl radical , producing centrilobular hepatic necrosis and steatosis—zone 3 is enzyme-rich and relatively hypoxic. Ethanol induction of CYP2E1 is a classic potentiator in teaching scenarios.

n-Hexane is metabolized to 2,5-hexanedione , which cross-links neurofilaments and produces giant axonal peripheral neuropathy (sensorimotor, often beginning in long axons). Methyl ethyl ketone can potentiate that pathway. This is not optic-nerve formate injury and not CNS methylmercury injury.

Methanol is oxidized by alcohol dehydrogenase to formaldehyde and then to formate . Formate causes anion-gap metabolic acidosis and injures the optic nerve and retina (visual loss, putaminal injury in severe cases). Ethanol or fomepizole compete for ADH in clinical management; the examination skill is the organ and metabolite , not a treatment protocol.

Ionizing radiation

Separate stochastic effects from deterministic (tissue-reaction) effects. Stochastic effects (cancer; heritable effects in germ cells as a protection concept) have a probability that rises with dose; radiation-protection practice treats them as lacking a practical threshold. Deterministic effects (skin burns, cataracts as tissue reactions, marrow ablation, gastrointestinal mucosal denudation) have a threshold , and severity rises above it.

Acute radiation syndrome is a deterministic, high-dose, whole-body (or large partial-body) story. A whole-body X-ray absorbed dose of about 0.1 Gy (100 mGy) typically produces no acute clinical radiation syndrome —no prodromal nausea-vomiting picture, no hematopoietic collapse, no gastrointestinal denudation. Those syndromes appear at substantially higher doses; the hematopoietic syndrome is typically discussed beginning near 1 Gy and above, with gastrointestinal and neurovascular syndromes at still higher doses. Absence of an acute syndrome at 0.1 Gy is not absence of stochastic cancer hazard. Protection programs still treat 0.1 Gy as a dose at which cancer-risk concern is real. Do not call 0.1 Gy “non-hazardous” and do not claim it produces gastrointestinal ARS within hours.

Nanomaterials, air pollution, and selected natural toxins

Nanomaterials (often discussed in the 1–100 nm range) have high surface area per mass . Hazard tracks size, surface chemistry, shape (including high-aspect-ratio fibers), agglomeration, and solubility , not the marketing prefix “nano” alone. Poorly soluble low-toxicity (PSLT) particles (historical teaching examples include some titanium dioxide and carbon-black dusts) can drive rat lung overload : impaired clearance, chronic inflammation, and tumors at high lung burdens. Translating overload tumors to human occupational concentrations is a WoE problem, not an automatic Group 1 equivalent. High-aspect-ratio carbon nanotubes invite a fiber-pathogenicity discussion (length, biopersistence, frustrated phagocytosis) more than a PSLT overload discussion.

Air pollution: PM2.5 is a cardiovascular and pulmonary mortality hazard in epidemiology; ozone is an oxidant that inflames airways and drops FEV1. They are mixture and secondary-pollutant problems, not a single CAS-number bioassay.

Naturally occurring toxins (conceptual, not a field-guide):

Aflatoxin B1 (Aspergillus) is bioactivated to an epoxide , adducts DNA, and is a hepatocellular carcinoma hazard, historically with a p53 codon-249 signature in some high-exposure regions.

Botulinum toxin cleaves SNARE proteins at the neuromuscular junction → flaccid paralysis .

Tetrodotoxin blocks voltage-gated sodium channels → paralysis (puffer-fish teaching).

Ricin (Ricinus communis) is a ribosome-inactivating protein (A chain depurinates 28S rRNA) → severe gastrointestinal and systemic cytotoxicity.

Organ systems as a checklist

Walk the systems so a stem cannot hide in an unnamed organ:

Blood / marrow — benzene, lead (heme), radiation at deterministic marrow doses, oxidizing methemoglobin formers.

Immune — stress involution versus true immunotoxicants; some metals and PAHs as teaching classes.

Gastrointestinal — corrosives, ricin, local irritant gavage effects versus systemic gut injury.

Liver — CCl4, aflatoxin, many CYP-bioactivated solvents; distinguish hypertrophy from necrosis (section 9.1).

Kidney — cadmium, inorganic mercury, some solvents and metals; proximal tubule versus glomerular patterns.

Respiratory — paraquat, ozone, PM2.5, Cr(VI), PSLT overload, fibers.

Nervous — OPs/carbamates, pyrethroids, lead, methylmercury, n-hexane, tetrodotoxin, botulinum.

Eye — methanol (formate), corrosives, some radiations (cataract as a tissue reaction).

Heart — some metals and solvents historically; PM2.5 as a population cardiovascular hazard.

Skin — arsenic, contact sensitizers, UV as a physical agent.

Reproductive — lead, radiation to gonads, selected solvents.

Endocrine — thyroid disruptors and some historical pesticide examples as a class, not a single CAS.

Developmental toxicants (original teaching)

Ethanol produces fetal alcohol spectrum injury: growth restriction, characteristic craniofacial features when exposure hits early craniofacial patterning, and CNS injury that is not confined to a single week. Brain development continues through pregnancy and beyond; “safe after gastrulation” is false.

Therapeutic retinoids (isotretinoin as the teaching drug) disrupt neural-crest migration: craniofacial malformations, conotruncal heart defects, thymic abnormalities, and CNS defects, with a critical window in early pregnancy. Adult dermatologic benefit does not cancel developmental hazard.

Valproate is associated with neural-tube defects when exposure occurs in the neural-tube closure window (early post-conception in humans). Folate biology is part of the counseling conversation; the examination point is the malformation class and timing .

ACE inhibitors produce a distinctive late-pregnancy pattern: fetal hypotension, anuria , oligohydramnios , pulmonary hypoplasia, and calvarial hypoplasia (ACE-inhibitor fetopathy). That hemodynamic renal story is primarily a second- and third-trimester hazard, not a “first two weeks only” story. Do not relocate it onto valproate’s neural-tube window, and do not relocate valproate onto ACE-inhibitor anuria.

  • Class or example Dominant mechanism (teaching level) Typical target
  • OP / carbamate insecticides AChE phosphorylation or carbamylation Nervous system, NMJ, autonomic
  • Pyrethroids Voltage-gated Na+ channel Nervous system
  • Paraquat Redox cycling in pneumocytes Lung (delayed fibrosis)
  • Lead Heme enzymes; developing CNS Blood, brain
  • Methylmercury Neuronal injury CNS, fetal brain
  • Cadmium / inorganic Hg Tubular injury Kidney
  • Cr(VI) Inhaled chromate Lung, nasal mucosa
  • Benzene Marrow toxicity Blood-forming organs
  • CCl4 CYP2E1 radical Centrilobular liver
  • n-Hexane 2,5-Hexanedione axonopathy Peripheral nerve
  • Methanol Formate Optic nerve
  • ~0.1 Gy whole-body X-ray Stochastic concern; no ARS Cancer risk, not acute syndrome
  • Aflatoxin B1 DNA-reactive epoxide Liver

Valproate / retinoids / ethanol / ACEI Patterning or fetal hemodynamics Neural tube, neural crest, CNS, fetal kidney

Scenario

A stem describes delayed pulmonary fibrosis after herbicide ingestion: think paraquat , not OP toxidrome. A stem describes wrist-drop and anemia in a battery worker: think lead , not n-hexane alone (though solvents can coexist). A stem describes optic blindness and acidosis after windshield-washer ingestion: methanol/formate , not n-hexane. A stem describes a 0.1 Gy diagnostic-range whole-body dose and asks whether gastrointestinal ARS will appear by evening: no acute clinical syndrome is expected ; cancer-risk discussion is the remaining hazard language. A stem describes an infant with a neural-tube defect after first-trimester anticonvulsant exposure: valproate pattern, not ACE-inhibitor oligohydramnios.

Traps

Treating every insecticide as an OP.

Calling paraquat an AChE inhibitor.

Equating toluene with benzene’s marrow-cancer hazard.

Assigning methanol’s optic injury to n-hexane, or n-hexane’s axonopathy to methylmercury.

Claiming 0.1 Gy whole-body X-ray produces acute GI radiation syndrome, or claiming it has zero cancer hazard.

Moving ACE-inhibitor fetopathy into the neural-tube closure window, or declaring ethanol safe after gastrulation.

Loading diagram... Agent class to typical target organ